NCIC CTG Abstractsto be presented at: 40th Annual ASCO Meeting June 5 to June 8, 2004, New Orleans, LA

Saturday, June 05, 2004
1:45 - 5:45pm
(Poster Discussion)
391 (Escalator 7) /
Lung Cancer I

Chair: Alex A. Adjei, MD, PhD; Fred R. Hirsch, MD, PhD

Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG (BR.18)
Presenter: Natasha B. Leighl, MD

Poster Number: 15 / Abstract No: 7038

Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC).

Presenter: Simron Singh, MD

Poster Number: 18 / Abstract No: 7041
Sunday, June 06, 2004
8:00 - 12:00pm
(General Poster Session)
Hall A (right half) /

Hematologic Malignancies

RECIST (Response Evaluation Criteria in Solid Tumors) applied to response in lymphoma
Presenter: Sarit Assouline, MDPoster Number: L6 / Abstract No: 6606
A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. (IND.141)
Presenter: Michael Crump, MD

Poster Number: L11 / Abstract No: 6611

8:45-9:00 am
(Oral Presentation)
278 (Escalators 5 &6) /
Sarcoma
Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. (SR.2)

Chair: Carol Jane Swallow, MD, PhD; Peter W.T. Pisters, MD

Presenter: Brian O'Sullivan, MD
Abstract No: 9007
7:45 - 8:00am
(Oral Presentation)
R04 (2nd Floor –
Escalators 1 & 2) /

Central Nervous System Tumors

Chair: Susan Marina Chang, MD

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. (CE.2)
Presenter: Gregory CairncrossAbstract No: 1500
8:00 - 12:00pm
(Poster Discussion)
291 (Escalator 7) /

Developmental Therapeutics: Molecular Therapeutics

Chair: Amita Patnaik, MD; Steven D. Averbuch, MD

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2’methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. (IND.153)

Presenter: Kim N. Chi, MD

Poster Number: 24 / Abstract No: 3033

8:00 - 12:00pm
(Poster Discussion)
R06 (2nd Floor –
Escalators 1 & 2) /

Gastrointestinal (Colorectal) Cancer

Chair: Paulo M. Hoff, MD; Tomislav Dragovich, MD, PhD
III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). (CO.14)

Presenter: Thomas A. Colacchio, MD

Poster Number: 13 / Abstract No: 3522
1:00 - 1:15pm
(Oral Presentation)
Hall G /

Chair: Alan Paul Venook, MD; Robert S. Warren, MD

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). (CO.15)

Presenter: Leonard Saltz, MD

Abstract No: 3500

1:30 - 1:45pm
(Oral Presentation)
283 (Escalator 7) /

Leukemia/Myeloma, including Transplantation

Chair: Lloyd Earl Damon, MD; Michael R. Bishop, MD

Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7.

Presenter: Chaim Shustik, MD

Abstract No: 6510

Sunday, June 06, 2004 …..continued
1:45 - 2:00pm
(Oral Presentation)
355 (Escalators 3 &4) /

Gynecologic Cancer

Chair: Paul Sabbatini, MD; Susan A. Davidson, MD

First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. (OV.14)

Presenter: Gunnar B. Kristensen, MD, PhD

Abstract No: 5003
2:30 - 2:45pm
(Oral Presentation)
355 (Escalators 3 &4) / Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. (OV.15)
Presenter: Jacobus Pfisterer, MD, PhD

Abstract No: 5005

1:30 - 1:45pm
(Oral Presentation)
Hall F /
Breast Cancer I

Chair:Kathy Miller, MD; Lisa A. Carey, MD

Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. (MA.17)

Presenter: Timothy Joseph Whelan, MS

Abstract No: 517
Sunday, 6/6/2004
9:15 - 9:30am
(Oral Presentation)
Hall G /

Lung Cancer I

Chair:David R. Gandara, MD; Hak Choy, MD

A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10

Presenter: Timothy L. Winton, MD

Abstract No: 7018
Monday, June 07, 2004
8:00 - 12:00pm
(Poster Discussion)
275 (Escalators 5 &6) /

Gynecologic Cancer

Chair: Franco Muggia, MD; Setsuko K. Chambers, MD

Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148.

Presenter: Kevin Victor Jasas, FRACP

Poster Number: 11 / Abstract No: 5019
9:15 - 9:30am
(Oral Presentation)
Auditorium (2nd Floor –
Escalators 6 & 7) /

Lung Cancer II

Chair: Mark A. Socinski, MD; Martin J. Edelman, MD

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial (BR.21)

Presenter: Frances A. Shepherd, MD

Abstract No: 7022

2:15 - 2:30pm
Hall F / Plenary Session (including Plenary Science of Oncology Lecture)
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. (CE.3)

Presenter: Roger Stupp, MD

Abstract No: 2
3:30 - 3:45pm
Hall F /

Chair:Eric J. Small, MD; Margaret A. Tempero, MD

Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). (CO.13)
Presenter: Jeff A. Sloan, PhD

Abstract No: 5

Tuesday, June 08, 2004
9:15 - 10:45am
Auditorium (2nd Floor –
Escalators 6 & 7) /
Best of Oncology/Society Abstracts

Chair: George W. Sledge, Jr., MD; Jamie H. Von Roenn, MD

Speaker: Paul Edward Goss, MD, PhD